Recent advances: Pulmonary medicine

British Medical Journal

Volumn 318, Issue 7177, 1999, Pages 171-176

  Roche, Nicolas ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LEUKOTRIENE; LOW MOLECULAR WEIGHT HEPARIN; THEOPHYLLINE; TINZAPARIN; TUBERCULOSTATIC AGENT;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DYSPNEA; EMPHYSEMA; HUMAN; INHALATIONAL DRUG ADMINISTRATION; KINESIOTHERAPY; LUNG EMBOLISM; LUNG VOLUME; ORAL DRUG ADMINISTRATION; PATIENT REFERRAL; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; STREPTOCOCCUS PNEUMONIAE; SUBCUTANEOUS DRUG ADMINISTRATION; TUBERCULOSIS; VACCINATION; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; COST BENEFIT ANALYSIS; LUNG TUBERCULOSIS; MORTALITY; PULMONOLOGY; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; HUMANS; LUNG DISEASES, OBSTRUCTIVE; PNEUMONIA, BACTERIAL; PULMONARY DISEASE (SPECIALTY); THROMBOEMBOLISM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 0033573613     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. 1 McFadden ER, Jr, Warren EL. Observations on asthma mortality. Ann Intern Med 1997;127:142-7.
2. 2 Cowie RL, Revitt SG, Underwood MF, Field SK. The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. Chest 1997;112:1534-8.
3. 3 Turner MO, Taylor D, Bennett R, Fitzgerald JM. A randomized trial comparing peak expiratory flow and symptom self-management plans for patients with asthma attending a primary care clinic. Am J Respir Crit Care Med 1998;157:540-6.
4. 4 Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax 1997;52:498-501.
5. 5 Bousquet J, Corrigan CJ, Venge P. Peripheral blood markers: evaluation of inflammation in asthma. Eur Respir J 1998;11:42-8s.
6. 6 Gustafsson LE. Exhaled nitric oxide as a marker in asthma. Eur Respir J 1998;11:49-52s.
7. 7 National Heart Lung and Blood Institute, World Health Organisation. Global initiative for asthma; global strategy for asthma management and prevention; NHLBI/WHO workshop report. Bethesda, MA: National Institutes of Health, 1995:1-176.
8. 8 Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med 1997;156:688-95.
9. 9 Reed CE, Offord KP, Nelson HS, Li JT, Tinkelman DG. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. The American Academy of Allergy, Asthma and Immunology Beclomethasone Dipropionate-Theophylline Study Group. J Allergy Clin Immunol 1998;101:14-23.
10. 10 Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-8.
11. 11 Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Bryne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.
12. 12 Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
13. 13 Roy A, Leblanc C, Paquette L, Ghezzo H, Cote J, Cartier A, et al. Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency and association with adrenal function. Eur Respir J 1996;9:226-31.
14. 14 Horwitz RJ, McGill KA, Busse WW. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998;157:1363-71.
15. 15 Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. Am J Respir Crit Care Med 1997;156:814-8.
16. 16 Cydulka RK, McFadden ER, Emerman CL, Sivinski LD, Pisanelli W, Rimm AA. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:1807-12.
17. 17 Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA 1996;275:1247-51.
18. 18 Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-9.
19. 19 Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997;112:336-40.
20. 20 Gosselink R, Troosters T, Decramer M. Exercise training in COPD patients: the basic questions. Eur Respir J 1997;10:2884-91.
21. 21 Donner CF, Muir JF. Selection criteria and programmes for pulmonary rehabilitation in COPD patients. Rehabilitation and chronic care scientific group of the European Respiratory Society. Eur Respir J 1997;10:744-57.
22. 22 COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52:S1-28.
23. 23 Keller CA, Ruppel G, Hibbett A, Osterloh J, Naunheim KS. Thoracoscopic lung volume reduction surgery reduces dyspnea and improves exercise capacity in patients with emphysema. Am J Respir Crit Care Med 1997;156:60-7.
24. 24 Tschernko EM, Wisser W, Wanke T, Rajek MA, Kirtzinger M, Lahrmann H, et al. Changes in ventilatory mechanics and diaphragmatic function after lung volume reduction surgery in patients wilh COPD. Thorax 1997;52:545-50.
25. 25 Martinez FJ, de Oca MM, Whyte RI, Stetz J, Gay SE, Celli BR. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997;155:1984-90.
26. 26 Szekely LA, Oelberg DA, Wright C, Johnson DC, Wain J, Trotman-Dickenson B, et al. Preoperative predictors of operative morbidity and mortality in COPD patients undergoing bilateral lung volume reduction surgery. Chest 1997;111:550-8.
27. 27 Russi EW, Stammberger U, Weder W. Lung volume reduction surgery for emphysema. Eur Respir J 1997;10:208-18.
28. 28 Chanez P, Vignola AM, O'Shaunessy T, Enander I, Li D, Jeffery PK, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997;155:1529-34.
29. 29 Keatings V, Jatakanon A, Worsdell Y, Barnes P. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:548.
30. 30 Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998;351:773-80.
31. 31 Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-12.
32. 32 Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. The study of men born in 1913. Arch Intern Med 1997;157:1665-70.
33. 33 Birdwell BG, Raskob GE, Whitsett TL, Durica SS, Comp PC, George JN, et al. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med 1998;128:1-7.
34. 34 Cogo A, Lensing AW, Koopman MM, Piovella F, Siragusa S, Wells PS, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ 1998;316:17-20.
35. 35 Perrier A, Desmarais S, Goehring C, de Moerloose P, Morabia A, Unger PF, et al. D-dimer testing for suspected pulmonary embolism in outpatients. Am J Respir Crit Care Med 1997;156:492-6.
36. 36 Ginsberg JS, Kearon C, Douketis J, Turpie AG, Brill-Edwards P, Stevens P, et al. The use of D-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis. Arch Intern Med 1997;157:1077-81.
37. 37 Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
38. 38 Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
39. 39 Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409-15.
40. 40 Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-62.
41. 41 Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997;337:663-9.
42. 42 Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
43. 43 Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Larkola K, Korppi M, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993;137:977-88.
44. 44 Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998;351:399-403.
45. 45 Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997;103:281-90.
46. 46. Sisk JE, Moskowitz AJ, Whang W, Lin SD, Fedson DS, McBean AM, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333-9.
47. 47 Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 1997;112:63-70.
48. 48 Moore RD, Chaulk CP, Griffiths R, Cavalcante S, Chaisson RE. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996;154:1013-9.